STATEMENT OF NEED

Esophagogastric cancers, including cancers of the esophagus, stomach, and gastroesophageal junction, represent the second most common cause of cancer-related deaths worldwide. In recent years, the treatment landscape of esophagogastric cancer has seen significant progress with the identification of novel biomarkers, including HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2, which are now used to guide treatment selection. Numerous novel targeted agents are being investigated in clinical trials, and HER2-targeted therapies and immunotherapies are approved for patients with advanced gastric and gastroesophageal junction cancers (Yu & Mehta, 2025). Therefore, it is crucial for members of the interdisciplinary cancer care team to remain up-to-date on biomarker testing methods and considerations for treatment selection. In Module 1 of this activity, Yelena Y. Janjigian, MD, Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, will discuss biomarker-guided approaches in esophagogastric cancer management.

TARGET AUDIENCE

Oncologists, gastroenterologists, pathologists, advanced practice providers, oncology nurses, and other healthcare professionals involved in the treatment of patients with esophagogastric cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

• Recognize patient characteristics and key actionable biomarkers in esophagogastric cancer that guide treatment selection
• Incorporate complementary interventions and interprofessional collaboration into a comprehensive care plan to enhance patient outcomes

REGISTRATION

There is no fee to participate in or claim CME/NCPD/AAPA credit for this activity.

PROVIDED BY

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 8/6/26. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development

A maximum of 0.5 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.5 ANCC contact hours of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 0.5 ANCC contact hours. 

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 0.5 ILNA points toward:

• Care Continuum (OCN®, CBCN®, CPHON®, AOCNP®)
• Oncology Nursing Practice (OCN®)
• Roles of the APRN (AOCNP®)
• Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)
• Treatment (OCN®, CBCN®, AOCNP®, CPHON®)

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Yelena Y. Janjigian, MD, discloses that she has served on an advisory board or panel or as a consultant for AbbVie, Amerisource Bergen, Ask-Gene Pharma, Arcus Biosciences, Astellas, AstraZeneca, Basilea Pharmacutica, Bayer, BeOne, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Geneos Therapeutics, Gilead Sciences, GlaxoSmithKline, Guardant Health, Health Advances, HMP Global, Imedex, Imugene, Inspirna, Lynx Health, Mashup Media, Master Clinician Alliance, Merck, Merck Serono, Mersana Therapeutics, PeerMD, Pfizer, Sanofi Genzyme, Seagen, Silverback Therapeutics, Suzhou Liangyihui Network Technology Co. Ltd., and Zymeworks; that she has received research funding from Astellas, AstraZeneca, Arcus Biosciences, Bayer, Bristol Myers Squibb, Cycle for Survival, Eli Lilly, Genentech/Roche, Inspirna, Merck, and Trascenta; and that she has is a stock/shareholder of Inspirna and Veda Life Sciences, Inc.  

i3 Health has mitigated all relevant financial relationships.